Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement Meeting Abstract
| Authors: | Bekaii-Saab, T. S.; Valle, J. W.; Borad, M. J.; Melisi, D.; Vogel, A.; Féliz, L.; Lihou, C. F.; Zhen, H.; Abou-Alfa, G. K. |
| Abstract Title: | Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement |
| Meeting Title: | 2019 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Jan 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-02-01 |
| Language: | English |
| ACCESSION: | WOS:000489107600016 |
| DOI: | 10.1200/JCO.2019.37.4_suppl.TPS462 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS462 -- Source: Wos |
